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Abstract
Background: Female sexual dysfunction (FSD) is an important but controversial problem with serious negative impact on
women’s quality of life. Data from twin studies have shown a genetic contribution to the development and maintenance of
FSD.
Methodology/Principal Findings: We performed a genome-wide association study (GWAS) on 2.5 million single-nucleotide
polymorphisms (SNPs) in 1,104 female twins (25–81 years of age) in a population-based register and phenotypic data on
lifelong sexual functioning. Although none reached conventional genome-wide level of significance (106-8), we found
strongly suggestive associations with the phenotypic dimension of arousal (rs13202860, P=1.2610
27; rs1876525,
P=1.2610
27; and rs13209281 P=8.3610
27) on chromosome 6, around 500kb upstream of the locus HTR1E (5-
hydroxytryptamine receptor 1E) locus, related to the serotonin brain pathways. We could not replicate previously reported
candidate SNPs associated with FSD in the DRD4, 5HT2A and IL-1B loci.
Conclusions/Significance: We report the first GWAS of FSD symptoms in humans. This has pointed to several ‘‘risk alleles’’
and the implication of the serotonin and GABA pathways. Ultimately, understanding key mechanisms via this research may
lead to new FSD treatments and inform clinical practice and developments in psychiatric nosology.
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Introduction
People vary in their enjoyment of sexual activity and
relationships – a source of significant mental wellbeing or
problems. Female sexual dysfunction (FSD) describes a cluster of
sexual symptoms including desire, arousal, orgasm and pain. It
appears relatively common in the general community and
population-level samples and is associated with a severe decrease
in quality of life in women [1–3]. The etiology of FSD is largely
unknown although several biological and psychological correlates
have been reported [3–5]. Nevertheless, no clear disease
mechanisms have emerged and this lack of knowledge has
hampered progress in both, psychiatric nosology and treatment
strategies for this growing burden on women’s psychiatric health.
Both, the Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition and International Classification of Diseases, Tenth Revision [6]
have arranged FSD into categories based largely on clinical
similarities, while in 1998 a consensus based definition and
classification system was designed by a panel of experts during the
International Consensus Development [7].
Biological research into FSD is woefully inadequate. Recent
twin studies suggest FSD is familial, with genetic factors
accounting for up to 51% of the phenotypic variance [8–10].
Twin studies also show evidence of genetic and environmental
contributions to psychological factors previously linked to FSD
(such as depression, anxiety, personality traits) [11–13]. Thus, it is
possible that some of the covariation between FSD and these
psychological correlates is explained by shared genetic and non-
genetic factors. However, there have been no large-scale studies to
identify single genes or gene variants robustly associated with FSD-
phenotypes (and no genome-wide association study - GWAS - has
ever been performed). To date, only a handful of candidate gene
studies of sexual desire and function exist. One candidate gene
study has linked serotonin polymorphisms (5HT2A) to reduced
sexual desire as a side-effect of SSRI-medication in 89 adult men
and women [14]. A further study reported an association between
the dopamine D4 receptor gene (DRD4) with self-reports of sexual
desire and arousal in 52 men and 92 women [15]. Interleukin-
1beta gene (IL-1B) has been correlated with variation in vulvar
vestibulitis syndrome scores, a broader phenotype for sexual pain
symptoms [16]. All these studies have methodological shortcom-
ings that limit their interpretation, primarily the candidate gene
design, small samples in mostly clinical populations (thus lacking
power to detect phenotype – DNA variant associations), and the
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phenotypic heterogeneity in sexual function. Moreover, none of
these studies examine women and FSD directly, making them
unsuitable for clarifying the etiological mechanisms under FSD at
the population-level.
We present here the results of the first GWAS of FSD in a
female population-sample published to date. By scanning a dense
set of genetic variants throughout the whole genome, we can test
replication of previously located genes from candidate gene
investigations and also identify novel genes that may lead to the
discovery of unknown biological pathways involved in the
development of FSD.
Materials and Methods
Participants
The TwinsUK adult twin registry based at St. Thomas’
Hospital in London is a volunteer cohort of over 10,000 twins
from the general population [17]. This twin population has been
involved in a wide range of studies on common traits and diseases
and has been shown to be representative of the general population
for a wide variety of medical, behavioral, and sexual traits
[3,18,19]. The twins were not selected on the basis of the
phenotypes being studied and were unaware of any hypothesis
being tested. All twins provided written informed consent and the
study was approved by St. Thomas’ Hospital Research Ethics
Committee.
All participants were dizygotic (DZ) pairs and monozygotic
(MZ) singleton twins of white European ancestry. A total of 1,489
subjects were included, all sexually active, heterosexual with no
history of any major psychological or medical condition
(depression, bipolar disorder, anxiety disorder, diabetes, multiple
sclerosis, endometriosis) and with all items on the Female Sexual
Function Index-Lifelong (FSFI-LL) available.
Sexual Dysfunction Phenotype
We used the recently developed 19-item Female FSFI-LL
questionnaire to measure long-term variation in female sexuality,
including periods of dysfunction and healthy function [20,21]. For
genetic analysis, the FSFI-LL is preferable to the ‘‘snapshot’’
measures used in some previous research and it better captures the
variation in enduring female sexual functioning required for
resolving the underlying genetic and non-genetic mechanisms of
FSD symptoms. The FSFI-LL assesses 6 dimensions of women’s
average sexual functioning ‘‘since they have been sexually active’’
including desire (2 items), arousal (4 items), lubrication (4 items),
orgasm (3 items), satisfaction (3 items), and pain (3 items). Desire
items are rated on a Likert-type scale ranging from 1 to 5. The
remaining items are rated from 0 to 5 with the supplementary
option ‘‘no sexual activity’’. Dimension scores are derived by
summing the item scores within each dimension and multiplying
the sum by the dimension factor weight [20]. The dimension
factor weighting converts the dimension scores to a consistent
range from 0 to 6, except for the desire, which has a dimension
score range from 1.2 to 6. Total scores are calculated via a simple
computer algorithm and low scores on the FSFI-LL indicate more
sexual problems and high scores indicate fewer problems. The
FSFI-LL has excellent psychometric properties for both, total- and
dimensions-specific scores, including test-retest reliability, internal
consistency, external/discriminant validity [20,21]. Exploratory
and confirmatory factor analyses have successfully reproduced the
original factor. According to response operator curve (ROC)-
derived cut-off scores, all dimensions and the total FSD score
displayed a good sensitivity to 1-specificity profile (as measured by
the area under the curve=AUC), with arousal (AUC=0.92)
displaying the best trade-off and desire the lowest
(AUC=67.55%). Overall, the FSFI-LL demonstrates excellent
comparability to the standard FSFI in terms of factor structure and
psychometric properties [21].
Detailed information on prevalences, potential environmental
risk factors and heritability estimates for FSD-symptoms in this
panel are reported elsewhere (3).
Genotyping, Quality Control, and Imputation
Genotyping was carried out using two genotyping platforms
from Illumina: the HumanHap 300k Duo for a part of the
Table 1. Top SNPs associated with sexual function related measures in a cohort of females of European ancestry.
Phenotype SNP CHR Position Locus Allele Effect* s.e.m P
Arousal rs13202860 6 87211973 A 20.421 0.08 1.213E207
Arousal rs1876525 6 87208811 C 20.421 0.08 1.213E207
Arousal rs13209281 6 87201368 A 20.443 0.09 8.329E207
Overall FSD rs4820255 22 35533796 PVALB C 20.366 0.076 1.687E206
Overall FSD rs4821535 22 35533452 PVALB G 20.366 0.076 1.687E206
Overall FSD rs2284024 22 35528729 PVALB T 20.366 0.077 1.838E206
Overall FSD rs5750311 22 35533286 PVALB G 20.367 0.077 2.104E206
Overall FSD rs739031 22 35532649 PVALB T 20.364 0.077 2.144E206
Overall FSD rs4821536 22 35533947 PVALB T 20.355 0.076 3.196E206
Lubrication rs2370759 22 32674978 EPC1 G 0.237 0.05 1.7E206
Lubrication rs11594963 10 32665742 EPC1 G 0.236 0.05 1.95E206
Lubrication rs11599044 10 32655451 EPC1 A 0.236 0.05 1.95E206
Lubrication rs10508773 10 32615450 EPC1 C 0.234 0.05 1.952E206
Lubrication rs16933243 10 32655141 EPC1 T 0.233 0.05 2.565E206
Lubrication rs11008865 10 32614848 EPC1 C 0.232 0.05 2.704E206
*Effect, b coefficient of linear regression. The effect sizes denote changes in phenotype unit per each additional copy of the reference allele.
doi:10.1371/journal.pone.0035041.t001
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for the remainder of the TwinsUK Cohort (n=599). Genotyping
with the HumanHap 300k Duo was conducted at the Centre
National de Ge ´notypage, Duke University, NC, USA; Helsinki
University, Finland; and the Wellcome Trust Sanger Institute,
Cambridge, UK. Genotyping with the Infinium 610k assay
(Illumina, Inc., San Diego, USA) for the remaining individuals
was conducted at the Centre for Inherited Diseases Research
(USA) and the Wellcome Trust Sanger Institute.
We applied stringent quality control (QC) criteria to the
genotype data. Genotypes were cleaned before analysis by
removing single-nucleotide polymorphisms (SNPs) or individuals
not fulfilling the QC criteria. The following QC filters were
applied for samples: call rate at least 95%; autosomal heterozy-
gosity between 33 and 37%. At the SNP level, Hardy Weinberg
Equilibrium (HWE) with P-value .10
24, Minor Allele Frequency
(MAF) at least 1%, and call rate at least 95% for SNPs with MAF
0.05 and above or at least 99% for SNPs with MAF less than 0.05.
We further visually inspected all intensity cluster plots of SNPs that
showed either an association for over-dispersion of the clusters,
biased no calling, or erroneous genotype assignment and discarded
all SNPs with any of these characteristics.
Genotypes from the TwinsUK were imputed using the
genotypes from the 3,855,687 autosomal markers available from
the HapMap Phase 2 CEPH population [22]. After imputation
using IMPUTE2 a total of 2,558,978 non-
monomorphic autosomal markers became available. After remov-
ing very rare markers (MAF,0.1) and markers in Hardy-
Weinberg Disequilibrium (p,e26) and individual with poor
imputation scores (,0.5), we obtained results from 2,287,762 loci
across the chromosome.
Statistical Analysis
Of the 1,489 women with recorded phenotype, genotype data
was available for 1,104 subjects after QC check. Data handling
and preliminary analyses were conducted using STATA software
(StataCorp., College Station, TX) and Merlin (PMID 11731797)
[23]. Association analyses were performed using MERLIN.
Ancestry was determined through principal component analysis
of individual genotypes (compared with subjects participating in
the HapMap Phase II standard populations).
All traits were included in multiple regression models, with age
and menopausal state included as covariates. Traits were inverse-
normalized to avert undue effects of non-normality of their
distributions. Regression slopes (b) are given as numbers of
standard deviation units per each additional copy of the effect
allele from this point onwards in the text. Given the experimental
size with hundreds of thousands of SNPs being analysed
individually, the commonly used ‘‘genome wide significance’’
(GWS) threshold was used which is the standard approximation
routinely set at 5610
28 [24]. However, given the cost of a strict
Bonferroni adjustment in results from relatively small datasets, we
considered all the associations with P#5610
25, as others have
done in other studies of similar sizes (UK IBD Genetics
Consortium, 2009; Amundadottir et al., 2009) [25,26].
Figure 1. Manhattan plots describing the association of 2.5 M SNPs with sexual arousal, lubrication and overall sexual functioning.
SNPs with P#10–6 are highlighted with a red circle (n=1104 females).
doi:10.1371/journal.pone.0035041.g001
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Racial and ethnicity stratification was checked through
eigenvector analysis and the above mentioned samples only
contained individuals of certified and pure European ancestry.
The genotyped samples were tested for population stratification,
by comparison to the three HapMap phase 2 reference
populations (CEU, YRI, CHB+JPT; www.hapmap.org) using
principal component analysis.
The mean age of participants in the study was 57 years (range
25–81 years). The GWAS analysis was performed using both
observed and imputed genotypes. The genomic inflation factor (l)
ranged from 0.98 to 0.99 for the different phenotypes, showing no
evidence for population stratification or inflated results due to
imputation. We identified 34SNPs with P-values ,10
25 of
association with FSD-related measures. These results are summa-
rized in Table 1. The most significant association was found
between rs13202860 on chromosome 6 and sexual arousal, with
P=1.2610
27. Two additional nearby SNPs showed P-values less
than 4610
27, (rs1876525, rs13209281; P=1.2610
27 and
8.3610
27, respectively; Table 1 and Figure 1). All three SNPs
were associated with arousal levels and spanned a region of 11 kb,
around 500 kbp upstream from the HTR1E (5-hydroxytryptamine
receptor 1E) locus (Figure 2 and Figure 3).
We also identified a locus on chromosome 22 with multiple
adjacent SNPs showing similar, albeit modest levels of associations
with overall sexual function (Table 1; Figure 1). Association was
maximal for rs4820255 and rs4821535 (both P=1.2610
26), two
SNP located 344 bp apart within intron 3 of the parvalbumin
(PVALB) gene. Similarly, six SNPs associated with lubrication
levels could be detected (P,3610
26 for all) on chromosome
10 near the EPC1 gene (Table 1; Figure 1).
Previous association studies have suggested several potential
candidates to be associated with FSD. More specifically, earlier
studies identified several variants on the dopamine D4 receptor
(DRD4) and the serotonin 2A receptor gene (5HT2A) to be linked
with levels of sexual desire and arousal (14,15). In this GWAS,
observed and/or imputed genotype information was available for
2 SNPs in the DRD4, 5 SNPS in the 5HT2A and 3 SNPS in the IL-
1B gene, and were hence evaluated for the replication of
previously reported associations. However, none of the markers
showed significant associations with the previously suggested
phenotypes (or with any of the outcome variables), as displayed
in Table 2.
Discussion
Here we reported the results of the first ever GWAS of female
sexual function levels in an unselected population-based cohort of
Figure 2. Association scatter plot for SNPs in the gene desert approximately 1Mbp upstream of the HTR1E gene. TwinsUK discovery
cohort. Negative logarithms of the P values for the association of each SNP with spherical equivalence are plotted. The lead SNP is plotted in diamond
shape, with the GWAS-analysis P value for that SNP indicated. Genotyped SNPs are plotted as squares, with the colour indicating the degree of
pairwise LD between the lead and neighbouring SNPs. Red indicates strong pairwise LD, with r2$0.8; orange indicates moderate LD, with
0.5,r2,0.8 yellow indicates weak LD, with 0.2,r2,0.5; and white indicates no LD, with r2,0.2. The recombination rates are shown as light blue line.
doi:10.1371/journal.pone.0035041.g002
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genome-wide level of significance (P,5610
28), but we found
strongly suggestive associations. Several studies of similar size have
considered any association with P-values #1610
25 as being
suggestive [25,26]. Moreover, numerous suggestive associations
below the genome-wide cut-off have been replicated in indepen-
dent studies, strongly suggesting that these are indeed real
associations rather than spurious results. For example, the Genetic
Analysis of Psoriasis Consortium & the Wellcome Trust Case
Control Consortium 2 in a GWAS study for psoriasis, replicated
many of the suggestive associations found by Nair and colleagues
including SNP nearby IL-23A and TNFIP3 with P#2610
25 and
P#1610
25, respectively [27,28]. Here, we identified several
strong suggestive associations with much stronger levels of
significance. Our strongest association (P 1.2x10
27), was on the
phenotypic dimension of arousal with a serotonin receptor gene
(HTR1E) which represents a strong biological candidate previously
shown to be involved in female sexuality. This potential
susceptibility locus resides within a ,1 Mbp segment of the
genome devoid of annotated genes, located about 500 kbp
downstream of the HTR1E gene. To assess the relationship
between rs13202860 and HTR1E we plotted the LD pattern of the
region. HapMap 3 data from two Caucasian populations (CEU
and TSI) shows that rs13202860, rs1876525 and rs13209281,
which show association with arousal in our study, are located in
different LD blocks than HTR1E (Figure 3). Although HTR1E is
an interesting candidate gene because of its known physiology, the
large distance between both loci, together with the evidence that
the significant SNP lie in other LD blocks than HTR1E clearly
suggest that these three SNPs are tagging independent associations
and that the causal polymorphism is more likely to regulate gene
expression rather than the protein structure of HTR1E. Enhancers
are elements of the genome that regulate gene expression of
nearby or distant genes and which can be located within gene
deserts [29]. Recent research suggests that polymorphisms in gene
Figure 3. Haploview LD plot. The plot uses the hapmapPhase3 data on the CEU and the TSI Caucasian populations and
encompasses an 800 kbp segment containing the associated SNP on chromosome 6 and HTR1E. The LD blocks were defined by
confidence intervals according to Gabriel and colleagues [45]. The x-axis corresponds to the genomic position in kb and the red triangles defined by
black lines represent LD blocks. The yellow arrow and the red box indicate the location of three GWAS associated SNP and the position of HTR1E,
respectively.
doi:10.1371/journal.pone.0035041.g003
Table 2. P-values of available markers in our GWAS, reported
to be associated with specific sexual problems in previous
candidate gene studies.
Genes SNP Associated phenotypes
P* P*
DRD4 Desire Arousal
rs3758653 0.7495 0.4242
rs11246226 0.2303 0.7294
HTR2A Desire Arousal
rs2760345 0.6594 0.1266
rs7326071 0.795 0.3783
rs2770293 0.03697 0.9446
rs2760347 0.9225 0.1493
rs4941570 0.04381 0.4987
Il-B Pain
rs1143643 0.6775
rs1143634 0.7558
rs1143633 0.6775
*Bonferroni corrected p-value.
doi:10.1371/journal.pone.0035041.t002
GWAS on FSD
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35041deserts could impact on disease by altering an enhancer element
[29–31]. Thus, it is possible that our causal variant is altering an
enhancer element located in the gene desert influencing HTR1E.
HTR1E encodes one of the families of highly conserved
serotonin receptor genes and is strongly expressed in neurons,
primarily in limbic brain regions (including caudate putamen,
claustrum, hippocampus, and amygdala) [32–33]. This high
degree of evolutionary conservation of genetic sequence suggests
an important physiological role of the HTR1E receptor in humans.
However, the actual function of the HTR1E receptor remains
unknown. Nevertheless, HTR1E is a gene with considerable
biological relevance to our phenotype of sexual functioning as it
shares amino acid sequence homologies and some pharmacolog-
ical characteristics with other 5-HT receptors (serotonin) and is
therefore closely related. Comparative research has documented
the critical role of serotonin receptors in modulating human and
non-human mammalian sexual behavior and functioning acting
on both central and peripheral (genital) sites [34–35]. SSRI
(selective serotonin reuptake inhibitors)-associated sexual side
effects, which include peripheral dysfunctions (e.g., erectile) as
well as central problems in desire and arousal are well documented
at high prevalence among users (up to 60%) [36]. These post-SSRI
sexual dysfunctions (PSSD) point strongly to the involvement of
serotonin receptors in human sexual behavior. Central serotoner-
gic activity affects female sexual functioning via limbic projections
of serotonin neurotransmitter are co-localized with norepinephrine
receptors – and both transmitters seem to work in conjunction in
the regulation of arousal and lubrication [35,37]. However, the
involvement of serotonin receptors in several reward-related
behavioral functions (e.g. satiety, sexual behavior, nociception,
escape, and stress) suggests that these receptors may function in the
‘‘higher-order’’ integration of rewarding behavior.
Our finding of a putative association between PVALB and
overall sexual functioning scores on the FSFI-LL is entirely new.
PVALB is a calcium-binding albumin protein present in GABAer-
gic interneurons, expressed predominantly in the prefrontal
cortex. Similar to serotonin, GABA is a major inhibitory
neurotransmitter. Several lines of research demonstrate that
GABA levels are associated with sexual function. Animal studies
show that GABA(A) and GABA(B) receptors are involved in the
inhibition of lordosis (a response shown by female animals
indicating sexual receptivity) as well as mediating the effects of
sex steroids such as estrogen in appetitive sexual behavior (e.g.,
sexual exploration) [37,38]. Elevated levels of stress have also been
shown to dampen sexual response in animal models as well as
being a significant psychological correlate of FSD in women
[39,40]. The number of hippocampal PV-containing GABAergic
interneurons is highly responsive to chronic external stressors,
offering the potential of stress-induced neuro-structural alterations.
The EPC1 gene encodes the enhancer of polycomb homolog 1
and is a component of the NuA4 histone acetyltransferase
complex. Previous research has suggested that this complex may
be required for the activation of transcriptional programs
associated with oncogene and proto-oncogene mediated growth
induction, tumor suppressor mediated growth arrest and replica-
tive senescence, and apoptosis. It has also shown to be involved in
skeletal muscle differentiation [41,42]. At this stage it is unclear
through which mechanisms EPC1 could have an effect on vaginal
lubrication and would need to be further investigated.
The present study had some methodological limitations and the
findings should be interpreted with caution. Our study sample
consisted mostly of peri- or postmenopausal women (70%). For
this reason, representativeness of our study might be limited to the
older female population, especially when considering that sexual
dysfunction is more common in peri- and postmenopausal than in
the non-climacteric period. However, prevalence rates of FSD in
our sample are comparable to estimates found in other, younger
populations [3]. Ideally, although similar populations are hard to
come by, it would be important to replicate our GWAS findings in
larger and independent samples before pursuing research into the
underlying biological disease pathways. Our sample size may be
one reason why our analysis did not reach conventional levels of
GWA significance. Unfortunately, as is common in this field, there
are no additional genotyped cohorts available with matching
phenotypic data that could have been used to replicate our
findings. Common diseases are typically influenced by multiple
environmental as well as genetic factors. Our case and control
participants may differ systematically for several of these
environmental characteristics (e.g. education, anxiety levels,
personality) which in turn could theoretically be related to genetic
variation and to the disorder itself. Future studies in much larger
sample sizes may be able to partition effects of known
psychological predictors of FSD (such as sexual distress and
anxiety levels) and if family-based differentiate genetic architecture
of these co-morbid traits. Current approaches to perform GWAS
are most successful if the common disease/common variant
(CDCV) assumption holds [43]. Currently, exome sequencing has
proven to be a powerful tool to identify rare coding variants and
has the potential to overcome certain GWAS limitations by
focusing on the identification of functional genomic structural
variants rather than markers. Gene-environment interaction is also
likely to have an influence on the development and maintenance
of FSD [44]. In this regard, high throughput sequencing
approaches would be again very useful as it can be used to
interrogate functional aspects of the genome to identify epigenetic
modifications such as DNA methylation, DNA-protein interaction,
chromatin accessibility, etc.
In summary, we report the first GWAS of female sexual
dysfunction symptoms in humans. This has pointed to several ‘‘risk
alleles’’ and the implication of the serotonin and GABA pathways
which we hope encourages further replication in large and
independent population-based cohorts and then biological inves-
tigation to elucidate possible mechanisms. Ultimately, understand-
ing key mechanisms via this research may lead to new FSD
treatments and inform clinical practice and developments in
psychiatric nosology.
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